P1235 BASELINE/EARLY PRESENCE OF KNOWN AND NOVEL RESISTANCE MUTATIONS IS ASSOCIATED WITH VIRAL FAILURE IN DIFFICULT-TO-TREAT PATIENTS TREATED WITH FIRST GENERATION PROTEASE INHIBITORS
Valeria Cento(Rostov State Medical University), Francesca Ceccherini‐Silberstein(University of Cologne), Daniele Armenia, Adriano Pellicelli(Carlo Forlanini Hospital), Giuliano Rizzardini, Laura Ambra Nicolini(Ospedale Policlinico San Martino), M. Siciliano, F. De Leonardis(University of Rome Tor Vergata), Simona Landonio(ASST Fatebenefratelli Sacco), Antonio Gasbarrini(Università Cattolica del Sacro Cuore), M. Aragri(University of Rome Tor Vergata), Monica Tontodonati(Azienda USL di Pescara), Sergio Babudieri(University of Sassari), A. Manunta(University of Sassari), Gloria Taliani(Sapienza University of Rome), Alessandro Mancon(Luigi Sacco Hospital), M. Angélico, Massimo Andreoni(University of Rome Tor Vergata), F.P. Antonucci(University of Rome Tor Vergata), Velia Chiara Di Maio(University of Rome Tor Vergata), L. Nosotti, I. Lenci(University of Rome Tor Vergata), Chiara Magni, Giustino Parruti(Azienda USL di Pescara), Valeria Micheli(ASST Fatebenefratelli Sacco), Maria Concetta Bellocchi(University of Rome Tor Vergata), Jacopo Vecchiet(University of Chieti-Pescara), Carlo Federico Perno(Centre International De Reference Chantal Biya), Daniele Di Paolo(University of Rome Tor Vergata), C. Sarrecchia(University of Rome Tor Vergata), Matteo Mura(University of Sassari), Antonio Di Biagio
Cited by 0
Related Papers
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
|Gastroenterology|2016|1k
Commensal Clostridia: leading players in the maintenance of gut homeostasis
|Gut Pathogens|2013|753